Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Alexander Burnett

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Burnett, Alexander

Item TypeName
Academic Article Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Concept Preoperative Period
Academic Article Phase I/II study of concurrent continuous-infusion topotecan with pelvic radiotherapy for locally advanced cervical carcinoma
Grant Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant 2004-27: A Phase I / II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 (efaproxiral) Administered to Patients Receiving a Course of Ci
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant AP 23573-07-205 A Randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Academic Article Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.
Grant Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant 2004-27: A Phase I / II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 (efaproxiral) Administered to Patients Receiving a Course of Ci
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
Grant OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE

Search Criteria
  • S Phase